No abstract

IntroductionThe use of prokinetic agents on post-pyloric placement of spiral nasojejunal tubes is controversial. The aim of the present study was to examine if metoclopramide or domperidone can increase the success rate of post-pyloric placement of spiral nasojejunal tubes.MethodsA multicenter, open-label, randomized, controlled trial was conducted in seven hospitals in China between April 2012 and February 2014. Patients admitted to the intensive care unit and requiring enteral nutrition for more than three days were randomly assigned to the metoclopramide, domperidone or control groups (1:1:1 ratio). The primary outcome was defined as the success rate of post-pyloric placement of spiral nasojejunal tubes, assessed 24 hours after initial placement. Secondary outcomes included success rate of post-D1, post-D2, post-D3 and proximal jejunum placement and tube migration distance. Safety of the study drugs and the tubes during the entire study period were recorded.ResultsIn total, 307 patients were allocated to the metoclopramide (n = 103), domperidone (n = 100) or control group (n = 104). The success rate of post-pyloric placement after 24 hours in the metoclopramide, domperidone and control groups was 55.0%, 51.5% and 27.3%, respectively (P = 0.0001). Logistic regression analysis identified the use of prokinetic agents, Acute Physiology and Chronic Health Evaluation (APACHE) II score <20, Sequential Organ Failure Assessment (SOFA) score <12 and without vasopressor as independent factors influencing the success rate of post-pyloric placement. No serious drug-related adverse reaction was observed.ConclusionsProkinetic agents, such as metoclopramide or domperidone, are effective at improving the success rate of post-pyloric placement of spiral nasojejunal tubes in critically ill patients.Trial registrationChinese Clinical Trial Registry ChiCTR-TRC-12001956. Registered 21 February 2012.

The first and the second critical micelle concentration (CMC(1) and CMC(2)) for three alkyltrimethylammonium bromide (C(n)TAB)/sodium dodecylsulfonate (AS)/H(2)O mixed systems, and CMC(1) for trimethylene-1,3-bis(dodecyldimethylammonium bromide) (12-3-12)/AS/H(2)O mixed system have been measured. The largest negative β(m) value means the strongest synergism between 12-3-12 and AS. The CMC(1) and CMC(2) for the C(n)TAB/AS/H(2)O mixed systems decrease with the increase of n. The equimolar mixed systems give the smallest CMC(1) values, whereas the CMC(2) values decrease with the increase of the composition of the surfactant with higher surface activity in the C(n)TAB/AS/H(2)O mixed systems. For the C(16)TAB/AS mixed systems far from equimolar, specific counterion effect on lowering CMC(1) enhances according to the Hofmeister series. There is slightly or no salt effect on the CMC(1) of the other wide composition range of C(16)TAB/AS/H(2)O mixed system. The pseudophase separation model coupled with the dissociated Margules model has been proposed and gives satisfactory description of the mixed CMC(1), the calculated micellar compositions are in well accordance with composition information from the ζ potential measurements. The addition of salt into the C(16)TAB/AS/H(2)O mixed system, leads to a certain degree of decrease in CMC(2). In addition to counterion effect, the co-ion effect on CMC(2) of the mixed system was explained using Collins' concept of matching water affinities.

BackgroundAlthough serum cystatin C (sCysC), urinary N-acetyl-β-d-glucosaminidase (uNAG), and urinary albumin/creatinine ratio (uACR) are clinically available, their optimal combination for acute kidney injury (AKI) detection and prognosis prediction remains unclear. We aimed to assess the discriminative abilities of these biomarkers and their possible combinations for AKI detection and intensive care unit (ICU) mortality prediction in critically ill adults.MethodsA multicenter, prospective observational study was conducted in mixed medical-surgical ICUs at three tertiary care hospitals. One thousand eighty-four adult critically ill patients admitted to the ICUs were studied. We assessed the use of individual biomarkers (sCysC, uNAG, and uACR) measured at ICU admission and their combinations with regard to AKI detection and prognosis prediction.ResultsAUC-ROCs for sCysC, uNAG, and uACR were calculated for total AKI (0.738, 0.650, and 0.683, respectively), severe AKI (0.839, 0.706, and 0.771, respectively), and ICU mortality (0.727, 0.793, and 0.777, respectively). The panel of sCysC plus uNAG detected total and severe AKI with significantly higher accuracy than either individual biomarkers or the other two panels (uNAG plus uACR or sCysC plus uACR). For detecting total AKI, severe AKI, and ICU mortality at ICU admission, this panel yielded AUC-ROCs of 0.756, 0.863, and 0.811, respectively; positive predictive values of 0.71, 0.31, and 0.17, respectively; and negative predictive values of 0.81, 0.97, and 0.98, respectively. Moreover, this panel significantly contributed to the accuracy of the clinical models for AKI detection and ICU mortality prediction, as measured by the AUC-ROC, continuous net reclassification index, and incremental discrimination improvement index. The comparable performance of this panel was further confirmed with bootstrap internal validation.ConclusionsThe combination of a functional marker (sCysC) and a tubular damage marker (uNAG) revealed significantly superior discriminative performance for AKI detection and yielded additional prognostic information on ICU mortality.Electronic supplementary materialThe online version of this article (doi:10.1186/s13054-017-1626-0) contains supplementary material, which is available to authorized users.